On April 29, the Federal Circuit affirmed an International Trade Commission decision, finding that Bio-Rad infringed the patent claims at issue; that 10X Genomics (10X) practiced the claims; and ...

If you want evidence that investors are excited about genetic testing stocks, just take a look at 10x Genomics (NASDAQ: TXG). Its shares skyrocketed 86% in 2020 and are up over 30% so far this ...

10x Genomics, a company focused on accelerating genomic discovery, today launched the Chromium Single Cell CNV Solution, which is the first scalable a ...

10x Genomics also disclosed that it had generated more than $100 million in the 30 months since commercially launching the first of its 25 products, spanning instruments, reagents, and software.

10x Genomics (TXG) reported $151.65 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 1.3%. EPS of -$0.30 for the same period compares to -$0.51 a ...

10x won’t say how many of both assays have been sold. Serge Saxonov, PhD, 10x’s co-founder and CEO, did say, however, that the assays are expected to draw new as well as existing customers ...

--10 x Genomics, Inc., a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024. Revenue of ...

10x Genomics, a company focused on accelerating genomic discovery, today announced that it had raised $125 million in funding. The funding included a 10x Genomics Completes $50 Million Series D ...

If you want evidence that investors are excited about genetic testing stocks, just take a look at 10x Genomics (TXG 3.40%). Its shares skyrocketed 86% in 2020 and are up over 30% so far this year.

For the quarter ended September 2023, 10x Genomics (TXG) reported revenue of $153.64 million, up 17.2% over the same period last year. EPS came in at -$0.51, compared to -$0.37 in the year-ago ...